Literature DB >> 12010891

Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.

A V Biankin1, S A Biankin, J G Kench, A L Morey, C-S Lee, D R Head, R P Eckstein, T B Hugh, S M Henshall, R L Sutherland.   

Abstract

BACKGROUND AND AIMS: Intraductal papillary mucinous tumours (IPMT) of the pancreas constitute a unique pathological entity with an overall incidence of associated invasive malignancy of 20%. The malignant potential of an individual IPMT cannot be accurately predicted. Preoperative estimation of the risk of associated invasive malignancy with IPMT would be of significant clinical benefit. As aberrations in cell cycle regulatory genes are associated with the progression of precursor pancreatic ductal lesions to invasive adenocarcinoma, we examined expression of key cell cycle regulatory genes in the cyclin D1/retinoblastoma pathway and the transforming growth factor beta/Smad4 signalling pathway in a cohort of patients with surgically resected IPMT.
METHODS: Sections of formalin fixed paraffin embedded pancreatic tissue from a cohort of 18 patients with IPMT were examined using immunohistochemistry for protein expression of cell cycle regulatory genes p16(INK4A), p21(CIP1), p27(KIP1), cyclin D1, pRb, and p53, as well as the cell signalling molecule Smad4. A comparison of expression levels was made between adenoma/borderline IPMT (10 patients) and intraductal papillary mucinous carcinoma (IPMC) (eight patients, four of whom harboured invasive carcinoma). Statistical analysis was performed using the chi(2) and Fisher's exact tests.
RESULTS: Aberrant expression of the proteins examined increased in frequency from adenoma/borderline IPMT to IPMC. Specifically, there was a significantly greater incidence of loss of p16(INK4A) expression in IPMC: 8/8 lesions (100%) compared with 1/10 (10%) adenoma/borderline IPMT (p<0.001). Similarly, loss of Smad4 expression was associated with IPMC: 3/8 (38%) versus adenoma/borderline IPMT 0/10 (p<0.03). Loss of Smad4 expression within the IPMT was the best marker for the presence of invasive carcinoma (p<0.001).
CONCLUSIONS: These data indicate that loss of p16(INK4A) and Smad4 expression occur more frequently in IPMC alone, or with associated invasive carcinoma, compared with adenoma/borderline IPMT. Aberrant protein expression of these cell cycle regulatory genes in IPMT and pancreatic intraepithelial neoplasia in the current model of pancreatic cancer progression suggest similarities in their development and may also represent the subsequent risk of invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010891      PMCID: PMC1773240          DOI: 10.1136/gut.50.6.861

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

Review 1.  Specificity, diversity, and regulation in TGF-beta superfamily signaling.

Authors:  E Piek; C H Heldin; P Ten Dijke
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

2.  Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.

Authors:  A V Biankin; J G Kench; A L Morey; C S Lee; S A Biankin; D R Head; T B Hugh; S M Henshall; R L Sutherland
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.

Authors:  R J Bova; D I Quinn; J S Nankervis; I E Cole; B F Sheridan; M J Jensen; G J Morgan; C J Hughes; R L Sutherland
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Intraductal papillary mucinous tumors of the pancreas.

Authors:  T Nakagohri; T Kenmochi; O Kainuma; Y Tokoro; T Asano
Journal:  Am J Surg       Date:  1999-10       Impact factor: 2.565

6.  K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas.

Authors:  K Satoh; T Shimosegawa; S Moriizumi; M Koizumi; T Toyota
Journal:  Pancreas       Date:  1996-05       Impact factor: 3.327

7.  Expression of oncogene products, anti-oncogene products and oncofetal antigens in intraductal papillary-mucinous neoplasm of the pancreas.

Authors:  T Terada; T Ohta; Y Nakanuma
Journal:  Histopathology       Date:  1996-10       Impact factor: 5.087

Review 8.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

9.  p53 oncogene mutations in three human prostate cancer cell lines.

Authors:  A G Carroll; H J Voeller; L Sugars; E P Gelmann
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  Intraductal papillary-mucinous neoplasm of the pancreas: a report of five cases with immunohistochemical findings.

Authors:  J G Kench; R P Eckstein; R C Smith
Journal:  Pathology       Date:  1997-02       Impact factor: 5.306

View more
  52 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Authors:  Adriana Handra-Luca; Sylviane Olschwang; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2011-10-16       Impact factor: 4.064

Review 3.  [Classification and malignant potential of pancreatic cystic tumors].

Authors:  I Esposito; A M Schlitter; B Sipos; G Klöppel
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 4.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

5.  [Intraductal neoplasms of the pancreas: cystic and common].

Authors:  G Klöppel; M Kosmahl; J Lüttges
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

Review 6.  Insights into the Pathogenesis of Pancreatic Cystic Neoplasms.

Authors:  Vrishketan Sethi; Bhuwan Giri; Ashok Saluja; Vikas Dudeja
Journal:  Dig Dis Sci       Date:  2017-05-12       Impact factor: 3.199

Review 7.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 8.  Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas.

Authors:  Aadhithya Raman; Anne Marie Lennon
Journal:  Visc Med       Date:  2018-06-13

9.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

10.  In vivo and in vitro propagation of intraductal papillary mucinous neoplasms.

Authors:  Hirohiko Kamiyama; Mihoko Kamiyama; Seung-Mo Hong; Collins A Karikari; Ming-Tseh Lin; Michael W Borges; Margaret Griffith; Angela Young; Alexis Norris-Kirby; Conrad Lubek; Masamichi Mizuma; Georg Feldmann; Chanjuan Shi; Hong Liang; Michael G Goggins; Anirban Maitra; Ralph H Hruban; James R Eshleman
Journal:  Lab Invest       Date:  2010-03-15       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.